Volume 12, Issue 10 (December 2018)
Qom Univ Med Sci J 2018, 12(10): 16-26 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Boozari Saravani F, Tafvizi F, Jaafari M R. The Effect of Synthesis of Pegylated Nanoliposome Containing DNAi on Reduction of BCL-2 Gene Expression in DLCL2 Cell Line. Qom Univ Med Sci J 2018; 12 (10) :16-26
URL: http://journal.muq.ac.ir/article-1-2142-en.html
URL: http://journal.muq.ac.ir/article-1-2142-en.html
1- Department of Biology, Parand Branch, Islamic Azad University
2- Department of Biology, Parand Branch, Islamic Azad University ,farzanehtafvizi54@gmail.com
3- Department of Pharmaceutics, Nano Technology Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences
2- Department of Biology, Parand Branch, Islamic Azad University ,
3- Department of Pharmaceutics, Nano Technology Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences
Abstract: (4394 Views)
Background and Objectives: Non-Hodgkin lymphoma is one of the common cancers that originates from lymphatic cells. The objective of this study was to assess the effectiveness of the DNAi containing pegylated nanoliposome (antisense drug) on decrease of BCL-2 gene expression.
Methods: In this study, to prepare DNAi containing pegylated nanoliposome, 3 formulations were prepared with 5, 10, and 15% combinations of PEG 2000 with certain ratios of phospholipid and cholesterols. After purification by a Zetasizer, the mean diameter of nanoliposome was measured. Drug efficacy was determined based on the standard curve of the drug. Cytotoxicity effect of the product was determined by treatment with 0.2, 0.5, and 0.8 µg/μl concentrations of each formulation in triplicate in vitro using MTT method. Then, BCL-2 gene expression was analyzed in DLCL2 cell line. Data were analyzed using one way ANOVA.
Results: The mean diameter of the DNAi containing pegylated nanoliposome was estimated to be 117 nm. The mean efficacy of the drug was 67%. The MTT assay on DLCL2 cell line indicated that the highest amount of cell growth inhibition was observed in treatment with pegylated nanoliposomes 10% (PEG10) and the concentration of 0.5 µg/μl. Also, BCL-2 gene expression was significantly decreased in DLCL2 cell line in all concentrations of PEG10 in 48 hours, and the lowest level of BCL-2 gene expression was observed in 0.5 µg/μl concentration.
Conclusion: PEG10 nanoliposome formulation has higher efficacy in drug preservation and release compared to other two synthesized liposomes. It seems that the synthesized nanoliposome has the potential for using in pharmaceutical industries.
Methods: In this study, to prepare DNAi containing pegylated nanoliposome, 3 formulations were prepared with 5, 10, and 15% combinations of PEG 2000 with certain ratios of phospholipid and cholesterols. After purification by a Zetasizer, the mean diameter of nanoliposome was measured. Drug efficacy was determined based on the standard curve of the drug. Cytotoxicity effect of the product was determined by treatment with 0.2, 0.5, and 0.8 µg/μl concentrations of each formulation in triplicate in vitro using MTT method. Then, BCL-2 gene expression was analyzed in DLCL2 cell line. Data were analyzed using one way ANOVA.
Results: The mean diameter of the DNAi containing pegylated nanoliposome was estimated to be 117 nm. The mean efficacy of the drug was 67%. The MTT assay on DLCL2 cell line indicated that the highest amount of cell growth inhibition was observed in treatment with pegylated nanoliposomes 10% (PEG10) and the concentration of 0.5 µg/μl. Also, BCL-2 gene expression was significantly decreased in DLCL2 cell line in all concentrations of PEG10 in 48 hours, and the lowest level of BCL-2 gene expression was observed in 0.5 µg/μl concentration.
Conclusion: PEG10 nanoliposome formulation has higher efficacy in drug preservation and release compared to other two synthesized liposomes. It seems that the synthesized nanoliposome has the potential for using in pharmaceutical industries.
Type of Study: Original Article |
Subject:
سلولی و مولکولی
Received: 2018/05/28 | Accepted: 2018/08/19 | Published: 2018/12/15
Received: 2018/05/28 | Accepted: 2018/08/19 | Published: 2018/12/15
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2008-1375
pISSN: 1735-7799
Email: journal[at]muq.ac.ir
j.mua.ac[at]gmail.com
